Invention Title:

MATERIALS AND PROCESSES FOR BIOENGINEERING CELLULAR HYPOIMMUNOGENICITY

Publication number:

US20260337579

Publication date:
Section:

Chemistry; metallurgy

Class:

C12N5/0696

Inventors:

Applicant:

Smart overview of the Invention

The patent application focuses on innovative methods and materials for achieving hypoimmunogenicity in cells. This involves bioengineering techniques to genetically modify or alter target genes, leading to the production of hypoimmunogenic cells. These engineered cells are less likely to trigger an immune response, making them useful in various medical applications, especially in cell therapies targeting complex diseases such as cancers and tumors.

Genetic Modification Techniques

Central to the application is the genetic modification of specific genes, such as the regulatory factor X (RFX) gene, to reduce the expression of certain proteins in human cells. This modification is crucial in creating hypoimmunogenic cells. The process may also involve altering additional genes, including the class II major histocompatibility complex transactivator (CIITA) gene, beta-2-microglobulin (B2M) gene, and CD58 gene, to further diminish immunogenic properties.

Production of Hypoimmunogenic Cells

The methods described include reprogramming immunogenic human cells into induced pluripotent stem (iPS) cells, followed by genetic modifications to produce hypoimmunogenic cells. These cells are then subjected to immune systems to evaluate their immunogenicity. The goal is to achieve a reduced immune response when these cells are introduced into allogeneic or non-MHC matched subjects, compared to non-modified cells.

Applications and Benefits

The engineered hypoimmunogenic cells have significant potential in therapeutic applications, particularly in cell therapy approaches that aim to treat various forms of neoplasia and cancer. By minimizing immune rejection, these cells can improve the efficacy and safety of treatments. The application also highlights the potential for these cells to reduce alloreactive T cell cytotoxicity, further enhancing their therapeutic value.

Advanced Cellular Compositions

The patent outlines the production of advanced hypoimmunogenic cellular compositions and systems. These compositions can be manufactured and utilized in various biomedical applications, offering new pathways for developing treatments that require reduced immunogenicity. The inclusion of T-cell receptors with specific chains in some embodiments further exemplifies the tailored nature of these engineered cells for specific therapeutic needs.